Sequential samples from 26 patients, who underwent clonal evolution of TP53 mutations (evolTP53 group) over the disease course, revealed for the first time an interplay between telomere length of subclones, BCR signaling activity, and CLL clinico-biological features. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.